Sonnet BioTherapeutics Holdings Inc. (SONN) skyrockets due to merger closing
Sonnet BioTherapeutics Holdings Inc. (SONN) currently trades at $11.21 and has grown by 128.74% today. SONN went up $6.36 from the previous closing price of $4.94. The high forecast for Chanticleer Holdings is $65.00 and the low is $40.00. The company’s market cap is $102.40 million with a 52 week high of $76.70 and a 52 week low of $4.61. SONN has changed in price by -28.03 per share in the last 12 months. Sonnet BioTherapuetics Holdings, formerly known as Chanticleer Holdings, Inc. announced that its merger with Sonnet BioTherapeutics, Inc. closed April 1, 2020. The combined company will operate under the name Sonnet BioTherapeutics Holdings, Inc., and its shares will commence trading on the Nasdaq Capital Market on April 2, 2020, under the ticker symbol “SONN”.
Sonnet BioTherapeutics Holdings Inc. has a weak EPS of -2.35. This means the company lost $-2.35 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article.
About Sonnet BioTherapeutics Holdings Inc:
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.